Navigating U.S. Tariffs in 2025: Why Reshoring Isn’t a Quick Fix
Every medical device manufacturer and hardware-product executive has been sweating the never-ending tariff-threat headlines lately (this is written March 2025).
The logic goes something like this: Move manufacturing back to the U.S., slap a “Made in USA” sticker on the box, and—poof!—your tariff problems disappear.
Except… they don’t.
Here’s the ugly truth about reshoring medical device manufacturing to the U.S.:
- ✅ It doesn’t eliminate tariffs on imported components.
- ✅ It doesn’t automatically qualify your product as “Made in USA.”
- ✅ It does increase your labor and operating costs.
That’s the tariff trap. Companies attempting to reshore manufacturing think they’re solving a problem, but they might be creating a new one—higher costs without real benefits.
Don’t get me wrong—as someone running a Canada-based medical device contract manufacturing company with U.S. clients, I want to see and help drive reshoring. But let’s be real: what was deconstructed over decades cannot be fixed in a few months.
So, before you start scouting locations in Ohio or Arizona, let’s break down why the real strategy isn’t just reshoring—it’s “tariff engineering.”
The “Made in USA” Myth: Why Your Supply Chain Is Still at Risk
The biggest mistake I see? Thinking that where you assemble your product determines whether you get hit with tariffs.
It doesn’t. Tariffs apply at the component level, not the final product level.
So if you move final assembly to the U.S., but your sensors come from Germany and your PCBs come from Taiwan, you’re still paying tariffs on those parts.
Example: How Tariffs Impact a Medical Device Supply Chain
Say you’re building a Class II medical device with this supply chain:
- Sensors from Germany → 10% tariff
- PCB assemblies from Taiwan → 15% tariff
- Plastic housings from Mexico → Tariff-free under USMCA (or maybe not… at the time of writing, there’s talk of a 25% tariff—only time will tell.)
- Final assembly in the U.S.
The problem? Even if your product qualifies as “Made in USA,” you’re still getting slammed with import duties on those German sensors and Taiwanese PCBs.
💡 Net result: You moved final assembly to the U.S., increased your labor costs, and still got punched in the face with tariffs.
That’s not a strategy. That’s just paying more for the same pain.
Government Contracts: The “Made in USA” Advantage (With a Catch)
Now, there is a legitimate reason to want “Made in USA” status—government contracts.
Take Veterans Affairs (VA) procurement. They strongly favor U.S.-made products under the Buy American Act (BAA). Winning VA contracts could justify higher domestic manufacturing costs, but only if you do the math first.
Scenario A (The Right Move)
- ✅ You reshore assembly to the U.S.
- ✅ You qualify for VA contracts that wouldn’t have been possible before.
- ✅ The revenue boost outweighs the increased costs.
Great. That makes sense.
Scenario B (The Expensive Mistake)
- ❌ You move assembly but still pay high tariffs on imported parts.
- ❌ You don’t actually qualify for BAA contracts because your component origin disqualifies you.
- ❌ You end up in a higher-cost, zero-benefit situation.
Not so great.
💡 The takeaway? “Made in USA” can unlock doors, but only if you meet the full criteria—and only if the revenue upside is bigger than the cost downside.
How to Claim U.S. Origin Through Substantial Transformation
Even if component tariffs still apply, certain final processing steps can help a product legitimately qualify as “Made in USA”—which can unlock government contract opportunities and potentially reduce tariff exposure.
Three Key Ways to Claim “Made in USA” Status
1️. Sterilization and Final Packaging (For Medical Device Manufacturers)
✅ Medical devices that require sterilization and certified packaging in the U.S. may be considered U.S. origin.
2️. Final Programming Rule
✅ If a microprocessor or chip undergoes its final firmware programming and activation in the U.S., that country may be considered the origin.
3️. Testing and Calibration Rule
✅ Some electronics are considered U.S. origin where final testing and calibration occur, particularly for complex, high-precision equipment.
The Medtech CEO’s Tariff Engineering Playbook – 5 Questions to Ask Before Reshoring
Before you blindly reshuffle your supply chain, here’s a five-question playbook that could save your company millions.
- What Are Your Total Import Tariff Costs on Components Today?
- Does Moving Final Assembly to the U.S. Change Your Tariff Classification?
- Are There Procurement Benefits to “Made in USA” That Outweigh Tariff Costs?
- Would a Hybrid Manufacturing Strategy Work Better?
- Have You Modeled the Financial Impact of Each Scenario?
Final Takeaways: What Medtech Leaders Must Do Now
Bottom line: Don’t get caught in the tariff trap.
- Moving final assembly to the U.S. (or even offshore to Vietnam) doesn’t eliminate tariffs on imported components.
- Reshoring everyone at once means costs will inflate, and lead times will extend.
- A hybrid strategy—U.S. assembly + nearshoring components—could be the best way to reduce costs while unlocking procurement benefits.
- Tariff engineering is the real game here—not just reshoring, but strategically designing a supply chain that optimizes for cost, compliance, and market access.
Before making a move, run the numbers. If you need help structuring your medical device supply chain for 2025 and beyond, let’s talk.
